2. シグナル伝達
  3. GPCR/G Protein
  4. GCGR

GCGR

Glucagon Receptor

GCGR

Related Products

PDF 0.98 MB

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

製品番号 製品名 製品効果 純度 構造式
  • HY-P3506A
    Retatrutide TFA Agonist 99.05%
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity.
    Retatrutide TFA
  • HY-103546
    BETP

    BETP

    		Agonist 99.48%
    BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.
    BETP
  • HY-P1024
    GLP-2(1-33)(human) Agonist 98.43%
    GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the GLP-2 receptor and stimulate the growth of intestinal epithelium.
    GLP-2(1-33)(human)
  • HY-19904
    Adomeglivant Antagonist 99.63%
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.
    Adomeglivant
  • HY-P10736A
    AMG133 peptide payload TFA Agonist 99.70%
    AMG133 peptide payload TFA is a GLP-1 analog agonist peptide. AMG133 peptide payload TFA potently activates GLP-1R and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload TFA can be used for the synthesis of AMG 133 (HY-164535).
    AMG133 peptide payload TFA
  • HY-13443A
    Exendin-4 acetate Agonist 99.87%
    Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
    Exendin-4 acetate
  • HY-P0054B
    GLP-1(7-36), amide TFA 98.82%
    GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
    GLP-1(7-36), amide TFA
  • HY-P2231A
    Cotadutide acetate Agonist 99.30%
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D).
    Cotadutide acetate
  • HY-112185A
    Orforglipron hemicalcium hydrate Agonist 99.71%
    Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete.
    Orforglipron hemicalcium hydrate
  • HY-P1023
    VIP(6-28)(human, rat, porcine, bovine)

    VIP(6-28)(human, rat, porcine, bovine)

    		Antagonist 98.09%
    VIP(6-28)(human, rat, porcine, bovine) is an effective antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) on cAMP.
    VIP(6-28)(human, rat, porcine, bovine)
  • HY-124622
    NNC-0640 Modulator 98.43%
    NNC-0640 is an effective negative allosteric modulator (NAM) of the human glucagon receptor (GCGR), with an IC50 value of 69.2 nM. NNC-0640 holds potential for research in the field of diabetes.
    NNC-0640
  • HY-P3463
    Beinaglutide 98.49%
    Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
    Beinaglutide
  • HY-P1160
    Bay 55-9837 Agonist 99.56%
    Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes.
    Bay 55-9837
  • HY-P3366
    Ecnoglutide Agonist 99.93%
    Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity.
    Ecnoglutide
  • HY-P3291
    Dapiglutide Agonist 98.52%
    Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects.
    Dapiglutide
  • HY-129658A
    TT-OAD2 Agonist 99.59%
    TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potential for diabetes treatment.
    TT-OAD2
  • HY-P10736
    AMG133 peptide payload 99.94%
    AMG133 peptide payload is a GLP-1 analog agonist peptide. AMG133 peptide potently activates GLP-1R, and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload can be used for the synthesis of AMG 133 (HY-164535).
    AMG133 peptide payload
  • HY-12525
    LGD-6972 Antagonist 98.0%
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research.
    LGD-6972
  • HY-P2231
    Cotadutide Agonist 99.11%
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D).
    Cotadutide
  • HY-P99357
    Crotedumab Inhibitor 99.22%
    Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes.
    Crotedumab
製品番号 製品名 / Synonyms Species Source
製品番号 製品名 / Synonyms Application Reactivity